Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses patient updates on hair loss treatment with Verteporfin after five months, as reported by Dr. Blake Bloxham. Patients voluntarily sent their progress pictures to Dr. Bloxham.

The conversation discusses arranging an interview with the developers of RU58841 to clarify its safety and reasons for halted research, with some users expressing concerns about potential risks and others citing financial reasons for the discontinuation of studies. Specific treatments mentioned include RU58841, minoxidil, and finasteride.

The user has maintained their hairline with finasteride for 5 years and saw no results from minoxidil. They are inquiring if tretinoin alone can cause hair regrowth.

A user who experienced hair loss and stopped finasteride 4.5 years ago is considering restarting treatment with finasteride and oral minoxidil, questioning if their hair follicles are still recoverable. Responses suggest that hair follicles may not die and can potentially be revived even after many years, with some users sharing personal success stories using treatments like minoxidil, finasteride, microneedling, and RU58841.

A user stopped finasteride after 15 years due to severe side effects, which improved after quitting. They maintained most of their hair and are considering alternatives like topical treatments or RU58841.

The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

The user plans to pause finasteride for two months to test its effects on mood and productivity, then switch to Pyrilutamide while monitoring hormone levels. Concerns are raised about potential hair loss and the effectiveness of Pyrilutamide compared to finasteride.

User experienced hair thinning after losing 100 lbs and started Dutasteride treatment. They faced side effects like fatigue, brain fog, and insomnia but no erectile dysfunction.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

The conclusion of the conversation is that the user, General-Switch-5722, has been using finasteride and minoxidil for over 2 years but is still experiencing hair loss. They are considering adding a low dose of RU58841 or topical dutasteride as potential treatments. Other users in the conversation have suggested switching to dutasteride or using oral minoxidil.

Dr. Toyos is recruiting more participants for a larger trial on hair loss treatments. The discussion mentions Minoxidil, finasteride, and RU58841 as potential treatments.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

The conversation discusses the safety and effectiveness of a hair loss drug, GT20029, and the possibility of infrequent application, with users hoping for once-daily use and speculating on the drug's duration of effect on the scalp. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses Dr. Blake Bloxham's experiment with Verteporfin for hair loss, with one person suggesting more doctors should try it as it seems beneficial. Another comment notes that results at 4-5 months were not very impressive.

A 51-year-old shared their hair recovery journey using finasteride, minoxidil, and dermarolling, noting significant improvement in hairline and temple areas. They emphasize consistency and patience, while another user suggests adding topical kx-826 and melatonin for additional benefits.

The user tried dutasteride for hair loss for 2.5 years but experienced drastic thinning and receding hairline. They decided to switch back to finasteride, along with minoxidil, LLLT, and ketoconazole, due to dissatisfaction with dutasteride's results and side effects.

The user shared their hair regrowth journey using treatments like dutasteride, minoxidil, microneedling, tretinoin, Nizoral, silica, biotin, and hormone replacement therapy (HRT) with cyproterone and estradiol. They reported substantial hairline improvement and some crown thinning, with hopes for further progress.

A user applied tretinoin to their scalp for hair loss and found brown particles in the cream. They are seeking information about these particles.

A dermatologist advised a patient to stop taking finasteride (fin) after turning 40 due to potential risk of aggressive prostate cancer. The patient and others in the conversation debated this advice, discussing the relationship between finasteride, prostate cancer, and hair loss, and considering alternatives like topical finasteride.

Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

A user shared their hair regrowth journey from ages 31 to 39, using finasteride, oral and topical minoxidil, and dutasteride. They experienced significant hair density improvement and temple regrowth, with increased hair growth as the only side effect.

A user shared their 75-day progress using oral minoxidil, finasteride, ketoconazole shampoo, and dermastamping for retrograde alopecia, reporting significant improvement and increased body hair without side effects. They also discussed quitting smoking and the potential correlation between early beard growth and male pattern baldness.

The user switched from finasteride and topical minoxidil to dutasteride and oral minoxidil due to side effects but is experiencing further hair recession. They plan to double the dosage, despite mixed feedback on the effectiveness and potential side effects of the treatments.

A user recommends using a microscope to assess hair density and track hair loss progress, finding it useful for evaluating treatment effectiveness, particularly with dutasteride and minoxidil. They advise against obsessing over hair loss and emphasize focusing on other meaningful life aspects.

The conversation is about a user who started using finasteride to address crown balding, noticing reduced hair shedding and halted progression of male pattern baldness. The user also used a dermal stamp and expressed optimism about potential regrowth, despite a slight decrease in libido.

A user shared their positive experience with the telehealth service DocBright, highlighting its affordability and effectiveness in prescribing finasteride, oral minoxidil, and ketoconazole. They noted the service's unique ability to provide a prescription at age 17 but criticized the unprofessional communication with the dermatologist.

The conversation is about a person considering participating in a study for Clascoterone, a topical cream for hair loss, and seeking advice on potential side effects. They have mild hair loss and are not currently using other treatments like finasteride.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.